The concept of ‘migrastatics’ allows the development of a new drug class that is neither cytotoxic nor antiproliferative but is solely directed towards inhibition of cancer cell motility. Given that the regulatory pathway is open, and migrastatic candidates have been described, it is the right time to enter a new era of antimetastatic treatment.
Related publications
- Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging. Šuráňová M, Ďuriš M, Štenglová Netíková I, Brábek J, Horák T, Jůzová V, Chmelík R, Veselý P. Biomed Opt Express. 2023 May 16;14(6):2689-2708. DOI
- Engine shutdown: migrastatic strategies and prevention of metastases. Raudenská M, Petrláková K, Juriňáková T, Leischner Fialová J, Fojtů M, Jakubek M, Rösel D, Brábek J, Masařík M.Trends Cancer. 2023 Apr;9(4):293-308 DOI
- Are We Ready for Migrastatics? Solomon J, Raškova M, Rösel D, Brábek J, Gil-Henn H. 2021. Cells. Jul 21;10(8):1845. DOI
- Solid Cancer: The New Tumour Spread Endpoint Opens Novel Opportunities. Fernandes, Michael, Daniel Rosel, and Jan Brábek. 2019. British Journal of Cancer 121 (7): 513–14. DOI
- Migrastatics: Redirecting R&D in Solid Cancer Towards Metastasis? Rosel, Daniel, Michael Fernandes, Victoria Sanz-Moreno, and Jan Brábek. 2019. Trends in Cancer. DOI
- Limits to Precision Cancer Medicine. Fernandes, Michael, Daniel Rosel, and Jan Brábek. 2017. The New England Journal of Medicine. DOI
- Cancer, Checkpoint Inhibitors, and Confusion. Fernandes, Michael, and Jan Brábek. 2017. The Lancet. Oncology 18 (11): e632 DOI
- Migrastatics—Anti-Metastatic and Anti-Invasion Drugs: Promises and Challenges. Gandalovičová, Aneta, Daniel Rosel, Michael Fernandes, Pavel Veselý, Petr Heneberg, Vladimír Čermák, Luboš Petruželka, Sunil Kumar, Victoria Sanz-Moreno, and Jan Brábek. 2017. Trends in Cancer 3 (6): 391–406. DOI